Poseida Therapeutics, Inc. (NASDAQ:PSTX) Short Interest Update

Poseida Therapeutics, Inc. (NASDAQ:PSTX) was the target of a significant drop in short interest during the month of July. As of July 31st, there was short interest totalling 3,140,000 shares, a drop of 39.8% from the July 15th total of 5,220,000 shares. Based on an average trading volume of 457,400 shares, the short-interest ratio is presently 6.9 days.

Poseida Therapeutics Stock Performance

Poseida Therapeutics stock traded up $0.04 during trading on Tuesday, hitting $2.93. The stock had a trading volume of 374,414 shares, compared to its average volume of 602,485. The stock has a market cap of $284.09 million, a price-to-earnings ratio of -2.46 and a beta of 0.53. Poseida Therapeutics has a 1 year low of $1.83 and a 1 year high of $4.27. The company has a quick ratio of 2.56, a current ratio of 2.48 and a debt-to-equity ratio of 0.97. The stock’s 50 day moving average is $3.04 and its two-hundred day moving average is $3.07.

Poseida Therapeutics (NASDAQ:PSTX) last announced its earnings results on Monday, August 5th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.11. The firm had revenue of $25.97 million for the quarter, compared to analyst estimates of $13.75 million. Poseida Therapeutics had a negative net margin of 127.48% and a negative return on equity of 121.01%. As a group, analysts predict that Poseida Therapeutics will post -1.61 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Poseida Therapeutics in a report on Tuesday, August 6th.

Hedge Funds Weigh In On Poseida Therapeutics

A number of institutional investors have recently modified their holdings of the stock. MCF Advisors LLC lifted its holdings in Poseida Therapeutics by 476.4% in the fourth quarter. MCF Advisors LLC now owns 247,024 shares of the company’s stock valued at $830,000 after acquiring an additional 204,170 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Poseida Therapeutics in the 4th quarter valued at approximately $36,000. Tower Research Capital LLC TRC raised its stake in shares of Poseida Therapeutics by 110.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 10,679 shares of the company’s stock worth $36,000 after buying an additional 5,606 shares during the last quarter. Cantor Fitzgerald L. P. acquired a new stake in Poseida Therapeutics during the fourth quarter worth approximately $169,000. Finally, Russell Investments Group Ltd. purchased a new position in Poseida Therapeutics in the first quarter valued at about $110,000. 46.87% of the stock is owned by hedge funds and other institutional investors.

About Poseida Therapeutics

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.